Maze Therapeutics
Latest round
- Series D
Last raised
- Dec 2024
Total raised
- $304M
Investors
- 20
About Maze Therapeutics
Maze Therapeutics, Inc. specializes in precision medicine development aimed at chronic kidney disease. Founded in 2018 in San Francisco, US, the company was established by Bernhard Klein, Jonathan Widawski, Maria Mesquita, and Thomas M. Currently, Maria Mesquita serves as the CEO. In February 2026, Maze Therapeutics, Inc.Maze Therapeutics specializes in developing precision medicines that target chronic kidney disease, leveraging significant advancements in human genetics to create innovative therapies. Their primary product pipeline includes treatments aimed at mimicking the effects of rare protective genetic variants to potentially halt or reverse the progression of kidney diseases, with a particular focus on APOL1 kidney disease. The company utilizes its proprietary Compass platform, which emphasizes variant functionalization, to inform the design of these medicines. Their offerings cater to a range of end users, including patients suffering from chronic kidney diseases and healthcare providers seeking effective treatment options.Maze Therapeutics engages in revenue generation through strategic partnerships and collaborations within the biotechnology sector, focusing on the development and commercialization of their precision medicines. Revenue streams may include contractual agreements with healthcare organizations or pharmaceutical partners for the joint development of therapies, as well as potential licensing deals for their proprietary technologies. The company’s flagship program targeting APOL1 kidney disease indicates a potential for substantial market demand, particularly from healthcare providers looking for novel treatment options. The financial structure of these transactions typically involves milestone payments associated with clinical trial progress, alongside royalties on future product sales as the therapies move towards market approval.
Who invested in Maze Therapeutics
20 investors across 3 rounds
See all investors in Maze Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Maze Therapeutics
Who invested in Maze Therapeutics?
Maze Therapeutics has 20 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Maze Therapeutics raised?
Maze Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Maze Therapeutics last raise money?
Maze Therapeutics's most recent round on record is a Series D, in Dec 2024.
What does Maze Therapeutics do?
Maze Therapeutics is a biotechnology company.
Where is Maze Therapeutics headquartered?
Maze Therapeutics is headquartered in San Francisco, US.
Which VCs invest in companies like Maze Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Maze Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Maze Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.